Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Robert M. Cox, Josef D. Wolf, Richard K. Plemper
Nature Microbiology (2020) Vol. 6, Iss. 1, pp. 11-18
Open Access | Times Cited: 385

Showing 51-75 of 385 citing articles:

Current Strategies of Antiviral Drug Discovery for COVID-19
Miao Mei, Xu Tan
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 96
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 95
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
David A. Meekins, Natasha N. Gaudreault, Jüergen A. Richt
Viruses (2021) Vol. 13, Iss. 10, pp. 1993-1993
Open Access | Times Cited: 94
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
Zilei Xia, M. Sacco, Yanmei Hu, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 4, pp. 1408-1421
Open Access | Times Cited: 85
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase
Jian‐Yuan Zhao, Saisai Guo, Dongrong Yi, et al.
Antiviral Research (2021) Vol. 190, pp. 105078-105078
Open Access | Times Cited: 82
High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, et al.
iScience (2020) Vol. 24, Iss. 1, pp. 101992-101992
Open Access | Times Cited: 79
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
Yoseph Caraco, Gordon Crofoot, Pablo Andrés Moncada, et al.
NEJM Evidence (2021) Vol. 1, Iss. 2
Closed Access | Times Cited: 79
An update of anti-viral treatment of COVID-19
Serap Şimşek Yavuz, İpek Komşuoğlu Çelikyurt
TURKISH JOURNAL OF MEDICAL SCIENCES (2021) Vol. 51, Iss. SI-1, pp. 3372-3390
Open Access | Times Cited: 78
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Ching‐Chi Lee, Chih‐Chia Hsieh, Wen‐Chien Ko
Antibiotics (2021) Vol. 10, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 76
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Seyed Mohammad Reza Hashemian, Mohammad Hossein Pourhanifeh, Michael R. Hamblin, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112517-112517
Open Access | Times Cited: 70
Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
Nicola Borbone, Gennaro Piccialli, Giovanni N. Roviello, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 986-986
Open Access | Times Cited: 69
Animal models for SARS-CoV-2
Chung-Young Lee, Anice C. Lowen
Current Opinion in Virology (2021) Vol. 48, pp. 73-81
Open Access | Times Cited: 66
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
Devendra Kumar, Neerja Trivedi
Biomedicine & Pharmacotherapy (2021) Vol. 139, pp. 111642-111642
Open Access | Times Cited: 66
Inhibitors of SARS-CoV-2 PLpro
Dale J. Calleja, Guillaume Lessène, David Komander
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 66
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review
Sri Masyeni, Muhammad Iqhrammullah, Andri Frediansyah, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3006-3016
Open Access | Times Cited: 62
Glycopeptide antibiotic teicoplanin inhibits cell entry of SARS-CoV-2 by suppressing the proteolytic activity of cathepsin L
Fei Yu, Ting Pan, Feng Huang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 58
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 58
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
Rina Hashimoto, Junya Takahashi, Keisuke Shirakura, et al.
Science Advances (2022) Vol. 8, Iss. 38
Open Access | Times Cited: 57
Cell response analysis in SARS-CoV-2 infected bronchial organoids
Emi Sano, Tatsuya Suzuki, Rina Hashimoto, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 55
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Matthew G. Johnson, Amy Puenpatom, Pablo Andrés Moncada, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 8, pp. 1126-1134
Open Access | Times Cited: 55
Plasticity in structure and assembly of SARS-CoV-2 nucleocapsid protein
Huaying Zhao, Ai Nguyen, Di Wu, et al.
PNAS Nexus (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 54
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir
Michael D. Waters, Stafford G. Warren, Claude L. Hughes, et al.
Environmental and Molecular Mutagenesis (2022) Vol. 63, Iss. 1, pp. 37-63
Open Access | Times Cited: 53
Review on molnupiravir as a promising oral drug for the treatment of COVID-19
Elham Zarenezhad, Mahrokh Marzi
Medicinal Chemistry Research (2022) Vol. 31, Iss. 2, pp. 232-243
Open Access | Times Cited: 49
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
Ikbel Hadj Hassine, Manel Ben M’hadheb-Gharbi, Luis Menéndez‐Arias
Viruses (2022) Vol. 14, Iss. 4, pp. 841-841
Open Access | Times Cited: 42

Scroll to top